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Abstract
Acute Respiratory Distress Syndrome (ARDS) constitutes a spectrum of severe acute respiratory
failure in response to a variety of inciting stimuli that is the leading cause of death and disability in
the critically ill. Despite decades of research, there are no therapies for ARDS, and management
remains supportive. A growing understanding of the complexity of the pathophysiology of ARDS,
coupled with advances in stem cell biology, has lead to a renewed interest in the therapeutic potential
of mesenchymal stem cells for ARDS. Recent evidence suggests that mesenchymal stem cells can
modulate the immune response to reduce injury and also increase resistance to infection, while also
facilitating regeneration and repair of the injured lung. This unique combination of effects has
generated considerable excitement. We review the biological characteristics of mesenchymal stem
cells that underlie their therapeutic potential for ARDS. We also summarise existing pre-clinical
evidence, evaluate the potential and pitfalls of using mesenchymal stem cells for treatment, and
examine the likely future directions for mesenchymal stem cells in ARDS.
Introduction
Acute Respiratory Distress Syndrome (ARDS) constitutes
aspectrum ofincreasinglysevereacuterespiratoryfailure.
It results from multiple causes (such as infection, trauma
and major surgery), and is the leading cause of death and
disability in the critically ill. ARDS is characterised
clinically by an acute onset, severe hypoxia, stiff lungs,
and the presence of an inflammatory pulmonary oedema
[1]. It is a devastating disease process and is the leading
cause of death and disability in critically ill adults and
children [2]. In the US alone, there are 200,000 new cases
annually, with a mortality rate of 40%, comparable to
that seen from HIV and breast cancer [3]. The outlook for
survivors of ARDS is also poor with a high incidence of
post-discharge cognitive impairment, depression and
muscle weakness, while the financial burden of ARDS
on society is considerable [4-5].
Despite decades of research, there are no therapies for
ARDS, and management remains supportive. Probable
reasons for the failure to find a successful therapy include
deficits in our understandingof the disease, coupled with
a focus on strategies that inhibit one aspect of a multi-
faceted injury process. More complex strategies, aimed at
reducing early injury while maintaining the ability of the
host to respond to insults, and/or enhance repair
following injury, are needed. These insights have led, in
part, to a renewed interest in the therapeutic potential of
mesenchymal stem cells. We will review the biological
characteristics of mesenchymal stem cells that underlie
their therapeutic potential for ARDS. We will also
summarise existing pre-clinical evidence, evaluate the
potential and pitfalls of using mesenchymal stem cells,
and examine the likely future directions for these cells in
ARDS.
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Despite being a focus of ongoing intensive research efforts
over four decades, there are no effective pharmacologic
treatments for ARDS. Many therapies have been evaluated
withoutsuccess,includinganti-oxidants[6],surfactant[7],
nitric oxide [8], corticosteroids [9-11], immunomodula-
tory agents [12-13], and most recently beta-2 agonists
[14]. Consequently, advances in the management of this
devastating disease have relied on improvements in
supportive measures, such as ‘protective’ mechanical
ventilation strategies [15], restrictive intravenous fluid
management approaches [16], and prone positioning of
severely hypoxaemic patients [17-18]. These and other
improvementsinsupportivecarehavedecreasedmortality
from ARDS over the last decade [19]. Nevertheless, the
failure of conventional pharmacologic approaches for
ARDS underlines the need to consider alternative ‘non-
conventional’ therapeutic approaches.
Why is it so difficult to find a therapy for ARDS?
ARDS is a challenging disease to study let alone treat. It is
a syndrome identified by the presence of clinical
parameters, including hypoxia, and bilateral infiltrates
on chest x-ray in the absence of left atrial hypertension
(to rule out cardiac failure). This leads to difficulties in
diagnosis. The patient population is heterogeneous in
terms of age, general health status, the cause of their
ARDS, and whether other organs are also damaged as
part of their critical illness. It is even uncertain if ARDS is
a single disease or a collection of different disease
processes with a similar phenotype. While about 40% of
patients with ARDS die, hypoxia is usually not the reason
for their deaths, with patients frequently dying from
other complications of their critical illness, such as
sepsis, shock, and failure of other organs [20].
More fundamentally, our understanding of the patho-
genesis of ARDS remains limited. The disease progresses
through relatively ill-defined stages, from the early acute
‘hyper-inflammatory’ stage to a later ‘fibrotic’ phase. The
acute phase is characterised by a complex series of inter-
related events, which may vary in response to the initial
insult (e.g. bacteria, trauma, major surgery), and involves
pro- and anti-inflammatory cytokines (e.g. TNF-a, IL-6,
IL-10) and effector cells (e.g. neutrophils, macrophages).
This inflammatory milieu increases alveolar-capillary
permeability resulting in alveolar oedema and leukocyte
infiltration, impaired surfactant function (normally it
prevents alveolar collapse, and protects the lung from
injury) with alveolar collapse, all resulting in impaired
gas exchange. Patients surviving this acute phase may
progress to a later fibrotic ‘repair’ phase, which can result
in long term scarring and damage to the lungs. This
phase may be complicated by impaired immunity,
susceptibility to infections, muscle weakness and a
need for prolonged respiratory support. However, the
transition between these phases is poorly defined, and
there is evidence of fibrosis and immune dysfunction
from the earliest stage of ARDS [1].
Given these complexities, it is perhaps not surprising that
strategies targeted at one aspect of the disease process
have been unsuccessful. This has led to a shift in thinking
towards more complex therapeutic approaches, aimed at
reducing early injury while maintaining host immune
competence, while facilitating (or at least not inhibiting)
repair following the acute injury phase. Could mesench-
ymal stem cells fit this new therapeutic paradigm?
Mesenchymal stem cells and why they
might be useful in ARDS
Mesenchymal stem cells are multipotent cells derived
from adult tissues that are capable of self-renewal and
differentiation into chondrocytes, osteocytes and adipo-
cytes. They were first isolated from the bone marrow in
1976 by Friedenstein and colleagues [21] and have
subsequently been isolated from many other tissues,
including fat, muscle, dermis, placenta and lung. The
derivation of mesenchymal stem cells from adult tissues,
their relative ease of isolation and enormous expansion
potential in culture make them attractive therapeutic
candidates [22]. They are immunologically well tolerated
[23], and can be transplanted from one individual to
another individual of the same species, an important
advantage for acute illnesses such as ARDS.
Mesenchymal stem cells are used in clinical trials for a
variety of diseases, including diabetes, myocardial infarc-
tion, Crohn’s disease, graft-versus-host disease, osteogen-
esis imperfecta, multiple sclerosis, and COPD (chronic
pulmonary obstructive disease), attesting to their safety in
humans. Interestingly, a recent study demonstrated that
mesenchymal stem cells improved lung function in
patients with myocardial infarction [24]. Also, a growing
body of pre-clinical data shows that mesenchymal stem
cells reduce lung injury caused by endotoxin [25-26],
pneumonia [27] and systemic sepsis [28]. Recently, the
clinical potential of mesenchymal stem cells for ARDS has
been considerably enhanced by a study demonstrating
thathumanmesenchymalstemcellscanreduceendotoxin-
induced injury in explanted human lungs [29]. All these
findings offer considerable hope that mesenchymal stem
cells may be a therapy for ARDS.
Do mesenchymal stem cells act by differentiating
into lung cells?
Early studies suggested that mesenchymal stem cells
might differentiate into lung epithelial cells, directly
Page 2 of 7
(page number not for citation purposes)
F1000 Medicine Reports 2012, 4:2 http://f1000.com/reports/m/4/2replacing the damaged and destroyed cells in the alveoli
in ARDS. Krause et al. found that a single bone marrow-
derived hematopoietic stem cell could give rise to cells of
different organs, including the lung, and demonstrated
that up to 20% of lung alveolar cells were derived from
this single bone marrow stem cell [30]. Kotton et al.
demonstrated that bone marrow derived cells engrafted
into pulmonary epithelium and exhibited characteristics
specific to lung epithelial cells [31]. Suratt and colleagues
found significant rates of engraftment of transplanted
hematopoietic stem cells in lung specimens from female
allogeneic hematopoietic stem cell transplant recipients
that received stem cells from male donors [32]. However,
more recent studies demonstrate that, while mesenchy-
mal stem cells reduce experimental lung injury, engraft-
ment rates are low [25,33-34], suggesting that direct
engraftment of mesenchymal stem cells in the lung is
unlikely to be of therapeutic significance (Table 1).
How might mesenchymal stem cells benefit
patients with ARDS?
While the precise mechanisms of action of mesenchymal
stem cells remain unclear, a number of important
insights have emerged.
Firstly, mesenchymal stem cells appear to modulate the
immune response to lung injury [25,34-35]. In contrast
to classic ‘anti-inflammatory’ strategies, mesenchymal
stem cells appear to decrease host damage arising from
the inflammatory response while enhancing host resis-
tance to sepsis. Mesenchymal stem cells decrease pro-
inflammatory cytokine expression [25-26], and secrete
anti-inflammatory agents, including interleukin 1 recep-
tor antagonist, interleukin-10, and prostaglandin E2
[28]. Mesenchymal stem cells also reduce lung neutro-
phil recruitment and modulate immune effector cell
activity.
Secondly, mesenchymal stem cells may augment the
host immune response to sepsis. Mesenchymal stem
cells reduced systemic sepsis induced by lung injury in
part again by secreting prostaglandin-E2, which stimu-
lated host macrophage IL-10 secretion [28]. Mesench-
ymal stem cells also secrete anti-microbial peptides
such as LL-37 (which may directly retard bacterial
growth [27]) and tumour-necrosis-factor-alpha-
induced-protein-6. In vivo, mesenchymal stem cells
increased bacterial clearance and enhanced host cell
phagocytosis in septic mice [35].
Thirdly, mesenchymal stem cells appear to aid the
regenerative response following injury, in part via the
secretion of cytoprotective agents [26,29,34,36].
mesenchymal stem cell secretion of angiopoeitin and
Table 1: Postulated mechanisms of action of mesenchymal stem cells in pre-clinical models of ARDS
Study Lung injury model MSC delivery route Postulated mechanism of action
Ortiz et al 2007 [33] Murine IT Bleomycin induced ALI IV delivery immediately post
injury
￿ Secretion of IL-1 receptor antagonist
￿ Inhibition of TNF-a production by macrophage and IL-1a
dependent T cell line
Xu et al 2007[51] Murine IP LPS induced ALI IV delivery 1h and 24h post
injury
￿ Production of soluble factors by mesenchymal stem cells
that promote an anti-inflammatory cytokine milieu
￿ Paracrine effect was enhanced by cell to cell contact
￿ Production of chemoattractants for mesenchymal stem cells
by lung cells
Gupta et al 2007 [25] Murine IT LPS induced ALI IT delivery 4h and 24h post
injury
￿ Paracrine effect by mesenchymal stem cells in down-
regulating the inflammatory response
￿ Engraftment rate <5%
Lee et al 2009 [29] Endotoxin induced ALI in ex-vivo
perfused human lung
IT 1/24h post injury ￿ Secretion of KGF by mesenchymal stem cells resulting in
improved endothelial permeability and restoration of
alveolar epithelium fluid transport
Nemeth et al 2009 [28] Murine CLP induced ALI IV 24h pre- / 1h post-injury ￿ Prostaglandin E2 dependent reprogramming of macrophage
to increase production of IL-10
Mei et al 2010 [35] Murine CLP induced ALI IV 6/24h post-injury ￿ Modification of inflammatory gene transcriptional activity
￿ Down regulation of the acute inflammatory response and
upregulation of pathways relevant to phagocytosis and
bacterial clearance
Krasnodembskaya et al
2010 [27]
E.coli pneumonia induced ALI IT 4/24h post-injury ￿ Secretion of the anti-microbial peptide LL-37 resulting in
increased bacterial clearance
Danchuk et al 2011 [26] Murine IT Endotoxin induced ALI IV, OA and IP human
mesenchymal stem cells
￿ Secretion of TSG-6 by mesenchymal stem cells resulting in
reduced neutrophil recruitment and activation
￿ Secretion of KGF
Abbreviations: IV,intravenous; IP, intra-peritoneal; LPS, lipopolysaccharide; IT, intra-tracheal; KGF, keratinocyte growth factor; CLP, caecal ligation and
puncture; OA, oropharyngeal aspiration; TSG-6, tumour necrosis factor alpha-induced protein 6; MSC, mesenchymal stem cell.
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and endothelial permeability and enhances resolution of
ARDS in pre-clinical models [26,29,34,36].
These diverse mechanisms of action of mesenchymal
stem cells, whereby they may favourably modulate the
immune response to reduce inflammatory injury while
maintaining immunocompetence, and facilitating recov-
ery and repair following injury, make them attractive
therapeutic candidates for ARDS.
What are the hurdles to clinical translation of
mesenchymal stem cells for ARDS?
A number of hurdles, however, remain before we can
start using mesenchymal stem cells in the clinic for
patients with ARDS. The optimal route of administra-
tion of mesenchymal stem cells is not known,
with various studies supporting the intravenous [28],
intra-tracheal [25,29] and intra-peritoneal [26] admin-
istration routes. The optimal dosage regimen for
mesenchymal stem cells is also unclear. Specifically,
the lower effective dose range and the efficacy of single
versus multiple dose regimens are not known. In
studies to date, the mesenchymal stem cells have
generally been given either prior to the injury or
immediately after the start of the injury process. This
does not reflect the clinical setting where the disease is
generally in progress for several days before treatment
is possible. Encouragingly, mesenchymal stem cells
have recently been demonstrated to enhance resolu-
tion and repair [37] following severe ventilation-
induced lung injury [38]. This suggests that mesench-
ymal stem cells may have true ‘therapeutic’ potential.
Another problem is that pre-clinical studies to date have
used relatively poorly defined, heterogeneous mesench-
ymal stem cells, which raises a number of issues. Firstly,
distinct sub-populations of mesenchymal stem cells vary
in terms of their differentiation potentialand their ability
to engraft in vivo [39-40]. This raises the possibility that
specific mesenchymal stem cell subpopulations may
have differing efficacies for ARDS. To complicate matters
further, unlike haematopoietic stem cells, mesenchymal
stem cells are not defined by a single marker and the
markers they express are not uniquely expressed by stem
cells [40-41]. While a set of minimal criteria for defining
mesenchymal stem cells has been developed [42], there
remains a lack of standardised protocols for isolation
and characterisation of mesenchymal stem cells. Further-
more, there is no validated method of measuring
mesenchymal stem cell bioactivity in vivo [43].
There are also deficits in our knowledge of the mechan-
isms of action of mesenchymal stem cells. One specific
concern is their effects on host immunity. Recent
experimental work showing that mesenchymal stem
cells can elicit a memory T-cell response in mice has
called into question their characterisation as 'immuno-
privileged cells' that can be transferred without immu-
nosuppression of recipients [44-45]. The picture is
further confounded by the fact that most experimental
experience in acute lung injury (ALI) is with murine and
rodent mesenchymal stem cells, which differ from
human mesenchymal stem cells on many grounds,
including immunosuppression and genomic stability
[26,46-47]. Reassuringly, however, clinical trials of
mesenchymal stem cells in human subjects, to date,
have not reported adverse immune side effects [48-49].
Nevertheless, caution is required in relation to immune-
modulating therapy in the aftermath of the anti-CD28
monoclonal antibody trial [50], particularly given the
very limited clinical experience with mesenchymal stem
cells in critically ill patients to date [24].
Conclusions
Mesenchymal stem cells are a promising therapy for
patients suffering from ARDS. Gaps remain in our
knowledge regarding the mechanisms of action of
mesenchymal stem cells and optimal mesenchymal
stem cell administration and dosage regimens, and
their safety in critically ill patients. However, the
evidence that mesenchymal stem cells can favourably
modulate the immune response to reduce lung injury,
while maintaining host immune-competence and also
facilitating lung regeneration and repair suggests that
they fulfil the requirement for more complex ther-
apeutic approaches to ARDS. We anticipate that these
remaining deficits in understanding will be addressed
in the future and that progression from pre-clinical
studies to clinical trials in patients with ARDS is likely
in the near future.
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